Skip to main content

Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML

Publication ,  Journal Article
Allen, SL; Erba, HP; Rizzieri, DA; O'Donnell, M; Powell, B; Lundberg, AS; Bennett, JM; Capizzi, RL
Published in: BLOOD
November 16, 2008

Duke Scholars

Published In

BLOOD

ISSN

0006-4971

Publication Date

November 16, 2008

Volume

112

Issue

11

Start / End Page

1019 / 1020

Location

San Francisco, CA

Publisher

AMER SOC HEMATOLOGY

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Allen, S. L., Erba, H. P., Rizzieri, D. A., O’Donnell, M., Powell, B., Lundberg, A. S., … Capizzi, R. L. (2008). Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML. BLOOD, 112(11), 1019–1020.
Allen, Steven L., Harry P. Erba, David A. Rizzieri, Margaret O’Donnell, Bayard Powell, Ante S. Lundberg, John M. Bennett, and Robert L. Capizzi. “Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.” BLOOD 112, no. 11 (November 16, 2008): 1019–20.
Allen SL, Erba HP, Rizzieri DA, O’Donnell M, Powell B, Lundberg AS, et al. Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML. BLOOD. 2008 Nov 16;112(11):1019–20.
Allen, Steven L., et al. “Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.” BLOOD, vol. 112, no. 11, AMER SOC HEMATOLOGY, Nov. 2008, pp. 1019–20.
Allen SL, Erba HP, Rizzieri DA, O’Donnell M, Powell B, Lundberg AS, Bennett JM, Capizzi RL. Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML. BLOOD. AMER SOC HEMATOLOGY; 2008 Nov 16;112(11):1019–1020.

Published In

BLOOD

ISSN

0006-4971

Publication Date

November 16, 2008

Volume

112

Issue

11

Start / End Page

1019 / 1020

Location

San Francisco, CA

Publisher

AMER SOC HEMATOLOGY

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology